Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Taxus Express stent real-world data shows outcomes after two years

Boston Scientific : 31 March, 2008  (New Product)
Boston Scientific has released results from an analysis of two-year data from more than 7,000 patients in the Taxus Arrive Registry programme.
The study was designed to evaluate the safety performance of the Taxus Express2 Paclitaxel-Eluting Coronary Stent System in patients treated in ‘real-world’ practice. Outcomes through two years in the simple- use (single vessel/stent) patient group confirmed the favourable results seen in similar patients enrolled in previous Taxus randomised clinical trials (the clinical trial cohort).

Results in the more complex expanded-use group also continued the expected slightly higher event rates than simple-use patients, but were still favourable through two years compared to the published outcomes of other treatment modalities for such patients. Analysis of the data was presented by John M Lasala, MD, PhD, at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago, USA.

'The extensive Arrive data show favourable and consistent outcomes in high- risk groups representing some of the most complex patients and lesions,' said Dr Lasala, professor of medicine, Washington University School of Medicine in St Louis. 'Outcomes in the simple-use patients in Arrive are consistent with results from the Taxus Stent cohorts in the Taxus randomised clinical trial programme, indicating that the Arrive methodology is very efficient in capturing adverse event outcomes. Overall, then, these results support the long-term performance of the Taxus Stent across the broad range of patients studied in these trials and registries.'

The pooled analysis included two-year outcomes for 7,033 patients in the Arrive 1 and 2 registries, including those with long lesions, bifurcations, Graft stenting, significant calcifications, and multi-vessel stenting. There were no differences in two-year safety rates (all death, Q-wave myocardial infarction (MI), or ARC definite/probable Stent thrombosis) between Arrive simple-use patients and the clinical trial cohort.

Adverse event rates at one year were expectedly higher for expanded-use versus simple-use Arrive patients, and included all death (4.2 percent vs 2.3 percent, respectively), all MI (1.8 percent vs 1.2 percent), target lesion revascularization (TLR) (6.2 percent vs 3.4 percent), and ARC Stent thrombosis (2.2 percent vs 0.9 percent). However, Taxus Stent-related adverse event rates during the second year of follow-up were lower for both expanded-use and simple-use patients than in the first year. Overall rates for Taxus Stent- related events in Arrive were within expected ranges given the patient complexity.

Through two years, medically treated diabetic patients had a higher rate of all death (9.7 percent vs. 5.1 percent, p less than 0.0001) compared to non-diabetic patients but similar rates of TLR (8.1 percent vs 7.7 percent, p=0.63), MI (2.5 percent vs 2.2 percent, p=0.40), and ARC Stent thrombosis (3.0 percent vs 2.4 percent, p=0.13). Patients with Graft stenting or stenting of bifurcation lesions had significantly higher rates of ARC Stent thrombosis and TLR through two years, as expected given the complexity of the lesions treated.

'Our Arrive registry data provide valuable insights into the benefits of the Taxus Stent in treating the broad spectrum of disease seen in real-world interventional practice,' said Paul LaViolette, chief operating officer at Boston Scientific. 'The analysis reinforces data observed in our randomized clinical trials, showing positive long-term performance of the Taxus Stent.'

The safety and effectiveness of the Taxus Express Stent has not been established in lesions longer than 28mm, bifurcations, saphenous vein grafts, multi-vessel stenting or diabetics.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo